Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ajcp/aqab081 http://scihub22266oqcxt.onion/10.1093/ajcp/aqab081 34302455!8336596!34302455     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Clin+Pathol 2021 ; 156 (3): 370-380 Nephropedia Template TP {{tp|p=34302455|t=2021. Use, Safety Assessment, and Implementation of Two Point-of-Care Tests for COVID-19 Testing |pdf=|usr=}}{{34302455}} gab.com Text Use, Safety Assessment, and Implementation of Two Point-of-Care Tests for COVID-19 Testing JO: Am J Clin Pathol http://www.kidney.de/pget.php?&tw=1&pmid=34302455 #FOAvip OBJECTIVES: The Abbot ID NOW COVID-19 assay and Quidel Sofia 2 SARS Antigen FIA are point-of-care assays that offer rapid testing for severe acute respiratory syndrome coronavirus 2 viral RNA and nucleocapsid protein, respectively. Given the utility of these devices in the field, we investigated the feasibility and safety of using the ID NOW and Sofia assays in the public health response to the coronavirus disease 2019 pandemic and in future public health emergencies. METHODS: A combination of utilization and contamination testing in addition to a review of instrument workflows was conducted. RESULTS: Utilization testing demonstrated that both tests are intuitive, associated with high user test success (85%) in our study, and could be implemented by staff after minimal training. Contamination tests revealed potential biosafety concerns due to the open design of the ID NOW instrument and the transfer mechanisms with the Sofia. When comparing the workflow of the ID NOW and the Sofia, we found that the ID NOW was more user-friendly and that the transfer technology reduces the chance of contamination. CONCLUSIONS: The ID NOW, Sofia, and other emerging point-of-care tests should be used only after careful consideration of testing workflow, biosafety risk mitigations, and appropriate staff training. Twit Text FOAVip Use, Safety Assessment, and Implementation of Two Point-of-Care Tests for COVID-19 Testing ????Am J Clin Pathol http://www.kidney.de/pget.php?&tw=1&pmid=34302455 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34302455 #FOAvip English Wikipedia <ref>{{Cite pmid|34302455}}</ref> Use, Safety Assessment, and Implementation of Two Point-of-Care Tests for COVID-19 Testing #MMPMID34302455 Hahn M; Olsen A; Stokes K; Fowler RC; Gu R; Semple-Lytch S; DeVito A; Kurpiel P; Hughes S; Rakeman JL Am J Clin Pathol 2021[Aug]; 156 (3): 370-380 PMID34302455show ga OBJECTIVES: The Abbot ID NOW COVID-19 assay and Quidel Sofia 2 SARS Antigen FIA are point-of-care assays that offer rapid testing for severe acute respiratory syndrome coronavirus 2 viral RNA and nucleocapsid protein, respectively. Given the utility of these devices in the field, we investigated the feasibility and safety of using the ID NOW and Sofia assays in the public health response to the coronavirus disease 2019 pandemic and in future public health emergencies. METHODS: A combination of utilization and contamination testing in addition to a review of instrument workflows was conducted. RESULTS: Utilization testing demonstrated that both tests are intuitive, associated with high user test success (85%) in our study, and could be implemented by staff after minimal training. Contamination tests revealed potential biosafety concerns due to the open design of the ID NOW instrument and the transfer mechanisms with the Sofia. When comparing the workflow of the ID NOW and the Sofia, we found that the ID NOW was more user-friendly and that the transfer technology reduces the chance of contamination. CONCLUSIONS: The ID NOW, Sofia, and other emerging point-of-care tests should be used only after careful consideration of testing workflow, biosafety risk mitigations, and appropriate staff training. |*COVID-19 Testing[MESH] |*Pandemics[MESH] |*Point-of-Care Testing[MESH] |Antigens, Viral/*analysis[MESH] |COVID-19/*diagnosis/epidemiology/virology[MESH] |Containment of Biohazards[MESH] |Equipment Safety[MESH] |Feasibility Studies[MESH] |Humans[MESH] |Risk Assessment[MESH]Use, Safety Assessment, and Implementation of Two Point-of-Care Tests (epmc).pdf DeepDyve Pubget Overpricing